EIN Presswire: Prostate Cancer Live Feed Press Releases

Global Coronary Stents - Market Growth Analysis, 2009-2015

Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015

Global Coronary Stents - Market Growth Analysis, 2009-2015

Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015

Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

Latest Reports by Transparency Market Research

Feed Additives Market

Compound Feed Market

Osteoporosis Drug Market

Weight Management Market

China Osteoporosis Market

Latin America Energy-Efficient Lamps Market

Germany Baby Food Market

China Baby Food Market

Asia Pacific Public Safety Wireless Communication Market

EMEA Public Safety Wireless Communication Market

Latin America Public Safety Wireless Communication Market

Public Safety Wireless Communication Market

Cardiovascular Monitoring & Diagnostic Devices Market

Wind Turbine Market

Wind Energy Market

Prostate Cancer Minimally Invasive Surgery Market

Diabetes Devices & Drugs Market

About Us

ResearchMoz is the one stop online destination to find and buy market research reports. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Email: sales@researchmoz.com

http://www.researchmoz.com/

http://www.marketresearchreportsblog.com/

China Market Research

http://www.globalmarketresearchreports.com/

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948

ResearchMoz: Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016)

Wed, 08 Feb 2012 11:30:00 +0000

ResearchMoz: Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016)

PR Newswire

ALBANY, New York, February 8, 2012 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016)

Browse the full Report: http://www.researchmoz.com/global-drug-eluting-des-bare-metal-bms-and-other-coronary-stents-market-2011-2016-report.html

Browse All Coronary Stents Market Research Reports http://www.researchmoz.com/coronary-stents-market.htm

Browse All Cardiovascular Devices Market Research Reports & Industry Analysis

Browse All Transparency Market Research Reports & Industry Analysis

Related Reports on Stem Cells Market

Coronary Stents Market in India

Global Coronary Stents - Market Growth Analysis, 2009-2015

Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015

Global Coronary Stents - Market Growth Analysis, 2009-2015

Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015

Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

Latest Reports by Transparency Market Research

Feed Additives Market

Compound Feed Market

Osteoporosis Drug Market

Weight Management Market

China Osteoporosis Market

Latin America Energy-Efficient Lamps Market

Germany Baby Food Market

China Baby Food Market

Asia Pacific Public Safety Wireless Communication Market

EMEA Public Safety Wireless Communication Market

Latin America Public Safety Wireless Communication Market

Public Safety Wireless Communication Market

Cardiovascular Monitoring & Diagnostic Devices Market

Wind Turbine Market

Wind Energy Market

Prostate Cancer Minimally Invasive Surgery Market

Diabetes Devices & Drugs Market

About Us

Email: sales@researchmoz.com

http://www.researchmoz.com/

http://www.marketresearchreportsblog.com/

China Market Research

http://www.globalmarketresearchreports.com/

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948

SOURCE ResearchMoz

Third Peer-Reviewed Study Proves Botanical Formula Fights Prostate Cancer Without Toxicity

Wed, 08 Feb 2012 10:00:00 +0000

Third Peer-Reviewed Study Proves Botanical Formula Fights Prostate Cancer Without Toxicity

PR Newswire

SANTA ROSA, Calif., Feb. 8, 2012 /PRNewswire/ -- Scientists at Indiana University, Methodist Research Institute, study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology. This is the third published study from a major university to show significant results of this specific multi-nutrient prostate formula against the invasive behavior of aggressive prostate cancer cells, tumor growth and metastasis. The formula combines botanical extracts, phytonutrients, botanically-enhanced medicinal mushrooms, and antioxidants. (Learn more about the formula by visiting www.prostatehealthsolutions.org)

Lead researcher, Dr. Daniel Sliva says, "Multiple studies demonstrate that this prostate formula is a possible treatment for hormone refractory (androgen independent) prostate cancer."

Suppresses Aggressive Tumor Growth Without Toxicity
Results of the study show this prostate formula significantly suppressed tumor growth in aggressive, hormone refractory (androgen independent) human-prostate cancer cells. This study also analyzed the formula for potential toxicity, demonstrating it to be safe with no signs of toxicity at the highest dosages. (To view the study on Pubmed, visit www.ncbi.nlm.nih.gov/pubmed/22293856)

Researcher and formulator, Dr. Isaac Eliaz says, "This study is a milestone in the research of this formula, demonstrating its safety and effectiveness in treating human prostate cancer in an animal model. These positive results offer a significant contribution to the field of prostate cancer research, and add to the growing body of published data substantiating the role of natural compounds in the treatment of prostate cancer."

Results of the study show that the oral administration of the formula produced a statistically significant 27% suppression of tumor growth, compared to controls. The study was performed using a xenograft tumor model of human prostate cancer in mice.

Inhibits Genes Involved in Tumor Growth and Metastasis
Even more important, in addition to significant reduction in tumor volume, results showed inhibition of the expression of several genes involved in cancer proliferation and metastasis. Three prostate cancer-related genes (IGF2, NRNF2 and PLAU/uPA) that were suppressed by this formula not only control aggressive prostate tumor growth, but also relate to the metastatic potential. It is metastasis that makes prostate cancer deadly. The formula also significantly increased the expression of a gene that fights against prostate cancer, CDKN1A, which works by specifically inhibiting other cancer-promoting cellular mechanisms.

By suppressing specific genes related to aggressive prostate cancer growth and proliferation, and increasing the expression of cancer-fighting genes, this integrative formula demonstrated multiple anti-cancer mechanisms and genetic targets. This pre-clinical in vivo study confirms previously published in vitro data, which also shows the ability of this formula to decrease the expression of PLAU/uPA genes in aggressive, hormone-independent prostate cancer cells.

Study Further Validates Earlier Results
This formula was previously studied at research laboratories at Columbia University, New York, NY and at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, Indianapolis, IN. These published studies showed significant results in this formula's ability to inhibit prostate cancer growth and proliferation.

"In summary, this dietary supplement is a natural compound for the possible therapy of human hormone refractory (independent) prostate cancer," says Dr. Sliva. Ongoing research on this formula in prostate cancer models continues to show encouraging results, and additional studies are forthcoming.

For more information about this groundbreaking study or to interview Dr. Isaac Eliaz, call (707) 583-8622 or email amy@dreliaz.org.

Source:
ProstaCaid™ inhibits tumor growth in a xenograft model of human prostate cancer (http://www.ncbi.nlm.nih.gov/pubmed/22293856)

About Better Health Publishing:
Better Health Publishing (BHP) focuses on the publication of key works promoting health and wellness. BHP believes that education and accessible information are the core components of a healthy and sustainable society.

SOURCE Better Health Publishing

Biomarkers Market (Discovery Technologies, Applications & Indications) - Global Trends, Opportunities & Forecasts (2011 - 2020)

Wed, 08 Feb 2012 09:48:36 +0000

Biomarkers Market (Discovery Technologies, Applications & Indications) - Global Trends, Opportunities & Forecasts (2011 - 2020)

PR Newswire

NEW YORK, Feb. 8, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers Market (Discovery Technologies, Applications & Indications) – Global Trends, Opportunities & Forecasts (2011 – 2020)

http://www.reportlinker.com/p0769003/Biomarkers-Market-Discovery-Technologies-Applications--Indications-–-Global-Trends-Opportunities--Forecasts-2011-–-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Biomarkers Market (Discovery Technologies, Applications & Indications) – Global Trends, Opportunities & Forecasts (2011 – 2020)

A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic response to a therapeutic intervention. Biomarkers are classified in different ways based on different parameters such as on the basis of their application, their characteristics and on their usage in decision making in early drug development. With drug development facing challenges from ever increasing cost of developing drugs and rise in the failure rate for drugs in phase II and III clinical trials, biomarkers are being employed on large scale by pharmaceutical companies to overcome these challenges. Also the advent of personalized medicine and companion diagnostics is witnessing a strong presence of use of biomarkers and holds to be a big opportunity for the overall biomarker market.

The global biomarker market is also growing due to emergence of several new companies, providing advanced technology platforms in areas such as bioinformatics, genomics, metabolomics, transcriptomics, proteomics, and pharmacogenomics. Scientific progress in these areas likely to be a key driver for further biomarker research to improve sample throughputs, enhance detection levels, and generate multiple biomarker panels with increased utility in diagnostics, preclinical research, clinical trials and product commercialization.

This report studies the global biomarker market divided into global discovery technologies market, global application market across major indications which is given as a different segment; Global biomarker indication market over the forecast period (2011-2020). The global biomarker market is valued at $13.16 billion in 2011 growing at a steady pace of CAGR 14.40% to reach $25.79 billion by 2016. The biomarker discovery technology market is the major contributor of this market followed by the application market. Oncology is seen to be the largest indication in terms of revenue but cardiology is the fastest growing indication with a CAGR of 16.24% from 2011 to 2016. North America is leading the market followed by Europe and Asia is the fastest growing region due to high adoption rate of high throughput technologies for biomarker discovery and rapid growth of IT industry in this region.

Players are implementing various growth strategies in the market to gain competitive edge. New products launch, agreements and collaborations, partnerships, joint ventures, mergers and acquisitions, were some of the major strategies adopted by the players during the study period between January 2009 and December 2011. Our research indicates that agreements, partnerships, collaborations, and new joint ventures form a major growth strategy in the Global Biomarker Market accounting for a 42% share in this market.

Scope of the report

This Biomarkers Market research report categorizes on the basis of discovery technologies and application market across major indications; forecasting revenues and analyzing trends in each of the following submarkets:

The report categorizes the global biomarker market as follows:

Discovery technologies (Omics technologies comprising genomics, proteomics, metabolomics, transcriptomics and epigenomics; imaging technologies comprising PET, SPECT, CT, MRI, ultrasound, and bioinformatics)

Services market (Assay production and development, biomarker testing, and biomarker validation)

Applications market (drug development and discovery, personalized medicine, and molecular diagnostics)

Indications (Oncology, cardiology, neurology, and others)

On the basis of geography:

North America

Europe

Asia

ROW

In addition to market data on the submarkets of the global biomarker market, each section of the report will identify and analyze the market trends, opportunities, and the factors driving or inhibiting market growth. The report will also draw a competitive landscape, in which it will profile 40 key market players.

TABLE OF CONTENTS

1 INTRODUCTION

1.1 KEY TAKE-AWAYS

1.2 REPORT DESCRIPTION

1.3 STAKEHOLDERS

1.4 RESEARCH METHODOLOGY

1.4.1 MARKET SIZE

1.4.2 KEY DATA POINTS FROM SECONDARY SOURCES

1.4.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

3.1 DEFINITION OF BIOMARKERS

3.2 BIOMARKERS & ITS TYPES

3.3 BIOMARKERS MARKET

3.3.1 MARKET SEGMENTATION

3.3.2 CHALLENGES & OPPORTUNITIES

3.3.2.1 Challenges

3.3.2.1.1 Variability

3.3.2.1.2 Ethical considerations & acceptability

3.3.2.2 Opportunities

3.3.2.2.1 Personalized medicine

3.3.2.2.2 Companion diagnostics

3.3.3 DRIVERS & RESTRAINTS

3.3.3.1 Drivers

3.3.3.1.1 High demand boosts the growth of the biomarker market globally

3.3.3.1.2 Strategic collaborations lead to increasing applications in the market

3.3.3.1.3 Technological advances contribute to growth

3.3.3.1.4 The rising prevalence of the disease forms

3.3.3.1.5 FDA support for biomarker development

3.3.3.2 Restraints

3.3.3.2.1 Low capital investment & cost-benefit hinders growth of biomarkers

3.3.3.2.2 Biomarkers not a profitable market for small organizations

3.3.3.2.3 Sample collection & storage

3.3.3.2.4 Limited biomarker validation

3.3.3.2.5 Need for new R&D models with greater precision & flexibility

4 GLOBAL BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES 4.1 INTRODUCTION 4.2 IMAGING TECHNOLOGIES FOR BIOMARKER DISCOVERY 4.2.1 POSITRON EMISSION TOMOGRAPHY (PET) 4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY(SPECT) 4.2.3 ULTRASOUND 4.2.4 MAGNETIC RESONANCE IMAGING (MRI) 4.2.5 COMPUTED TOMOGRAPHY (CT) 4.3 OMICS TECHNOLOGIES FOR BIOMARKER DISCOVERY 4.3.1 PROTEOMICS 4.3.1.1 Mass spectrometry 4.3.1.1.1 MALDI mass spectrometry 4.3.1.1.2 Imaging mass spectrometry 4.3.1.2 2D Gel Electrophoresis 4.3.1.3 Protein microarray technology 4.3.1.4 Antibody array technology 4.3.1.5 Peptide array technology 4.3.2 GENOMICS 4.3.2.1 Whole genome sequencing 4.3.2.2 Genotyping 4.3.2.3 Epigenetics 4.3.3 TRANSCRIPTOMICS 4.3.3.1 Microarrays 4.3.3.2 Gene expression profiling 4.3.4 METABOLOMICS 4.3.4.1 Capillary electrophoresis 4.3.4.2 Mass spectrometry based kits 4.3.4.3 Nuclear Magnetic Resonance(NMR) 4.4 BIOINFORMATICS 4.4.1 CLUSTER ANALYSIS 4.4.2 STATISTICAL ANALYSIS 4.4.3 CELL SIGNAL PATHWAYS 4.4.4 COMPUTER AIDED DESIGN 4.4.5 DATA MINING 4.4.6 PROTEIN INTERACTION MAPS

5 SERVICES MARKET OF BIOMARKERS

5.1 INTRODUCTION

5.2 CLINICAL

5.2.1 SAMPLE PREPARATION

5.2.2 ASSAY DEVELOPMENT

5.2.3 BIOMARKER VALIDATION & TESTING

5.2.3.1 Feasibility Studies and choice of assay & biomarker

5.2.3.2 Long lead time required for Biomarker Assay preparation

5.3 BIOINFORMATICS

5.3.1 FUNCTIONAL GENOMICS & PROTEOMICS DRIVE THE DEMAND FOR BIOINFORMATICS

6 BIOMARKER APPLICATION MARKET 6.1 INTRODUCTION 6.2 DRUG DISCOVERY & DEVELOPMENT 6.2.1 CLINICAL TRIALS 6.2.1.1 Preclinical Development 6.2.1.2 Phase I drug development 6.2.1.3 Phase II drug development 6.2.1.4 Phase III drug development 6.2.1.5 Phase IV drug development 6.3 PERSONALIZED MEDICINE 6.4 MOLECULAR DIAGNOSTICS 6.4.1 MOLECULAR DIAGNOSTICS IS A DYNAMIC & RAPIDLY BROADENING MARKET 6.4.2 TRENDS IN THE DIAGNOSTICS MARKET 6.4.3 CHALLENGES 6.4.3.1 Nucleic acids pose a challenge to the molecular diagnostics field 6.4.3.2 Molecular diagnostics market lacks a collaborated effort 6.4.4 DRIVER 6.4.4.1 Increase in the incidence of diseases spurs the growth of the diagnostics market 6.4.5 RESTRAINT 6.4.5.1 The "interest-information" restricts growth of molecular diagnostics 6.4.6 MOLECULAR DIAGNOSTICS IN MAJOR INDICATIONS 6.4.6.1 Oncology 6.4.6.2 Cardiology 6.4.6.3 Neurology 6.4.6.4 Other treatment areas 6.4.7 BIOMARKERS IN DIAGNOSTICS 6.4.8 BENEFITS OF MOLECULAR DIAGNOSTICS

7 BIOMARKER INDICATION MARKET

7.1 INTRODUCTION

7.2 ONCOLOGY BIOMARKER MARKET

7.2.1 ONCOLOGY BIOMARKER DISCOVERY MARKET

7.2.1.1 Genomics

7.2.1.2 Proteomics

7.2.1.3 Metabolomics

7.2.1.4 Transcriptomics

7.2.1.5 Other Omics

7.2.1.6 Imaging

7.2.2 DRUG DISCOVERY & DEVELOPMENT

7.2.3 CANCER TYPES

7.2.3.1 Ovarian Cancer

7.2.3.2 Breast Cancer

7.2.3.3 Bladder Cancer

7.2.3.4 Cervical Cancer

7.2.3.5 Prostate Cancer

7.2.3.6 Lung Cancer

7.2.3.7 Colorectal Cancer

7.3 CARDIOLOGY BIOMARKERS MARKET

7.3.1 CARDIOLOGY BIOMARKER DISCOVERY MARKET

7.3.1.1 Genomics

7.3.1.2 Proteomics

7.3.1.3 Metabolomics

7.3.1.4 Transcriptomics

7.3.1.5 Imaging

7.3.1.6 Bioinformatics

7.3.2 DRUG DISCOVERY & DEVELOPMENT

7.3.3 CARDIAC MARKERS, BY DISEASE TYPES

7.3.3.1 Acute Coronary Syndrome

7.3.3.2 Coronary artery disease

7.3.3.3 Stroke

7.3.4 CARDIOLOGY BIOMARKERS USED IN THE MARKET

7.4 NEUROLOGY BIOMARKER MARKET

7.4.1 NEUROLOGY BIOMARKER DISCOVERY MARKET

7.4.1.1 Omics technologies

7.4.1.2 Imaging Technologies

7.4.2 DRUG DISCOVERY & DEVELOPMENT

7.4.3 DISEASE TYPES

7.4.3.1 Alzheimer's disease

7.4.3.2 Parkinson's disease

7.4.3.3 Multiple sclerosis

7.4.3.4 Schizophrenia

7.4.3.5 Amyotrophic Lateral Sclerosis

7.4.3.6 Epilepsy

7.5 OTHER INDICATIONS BIOMARKER MARKET

7.5.1 OTHER INDICATION BIOMARKER DISCOVERY MARKET

7.5.1.1 Omics technologies

7.5.1.2 Imaging technologies

7.5.2 DRUG DISCOVERY & DEVELOPMENT

7.6 DISEASE TYPES

7.6.1 HIV

7.6.1.1 Immunological & Virological Markers in HIV Infection

7.7 RENAL FAILURE

7.8 ARTHRITIS

7.9 TUBERCULOSIS

7.10 DIABETES

8 GEOGRAPHICAL ANALYSIS 8.1 INTRODUCTION 8.2 NORTH AMERICA 8.3 EUROPE 8.4 ASIA 8.5 ROW

9 COMPETITIVE LANDSCAPE

9.1 KEY STRATEGIES

9.2 MERGERS & ACQUISITIONS

9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES

9.4 NEW PRODUCTS LAUNCH

9.5 OTHER DEVELOPMENTS

10 COMPANY PROFILES 10.1 ABBOTT LABORATORIES 10.1.1 OVERVIEW 10.1.2 FINANCIALS 10.1.3 PRODUCTS & SERVICES 10.1.4 STRATEGY 10.1.5 DEVELOPMENTS 10.2 ABCODIA LTD 10.2.1 OVERVIEW 10.2.2 FINANCIALS 10.2.3 PRODUCTS & SERVICES 10.2.4 STRATEGY 10.2.5 DEVELOPMENTS 10.3 AFFYMETRIX INC 10.3.1 OVERVIEW 10.3.2 FINANCIALS 10.3.3 PRODUCTS & SERVICES 10.3.4 STRATEGY 10.3.5 DEVELOPMENTS 10.4 AGILENT TECHNOLOGIES INC 10.4.1 OVERVIEW 10.4.2 FINANCIALS 10.4.3 PRODUCTS & SERVICES 10.4.4 STRATEGY 10.4.5 DEVELOPMENTS 10.5 AMGEN INC 10.5.1 OVERVIEW 10.5.2 FINANCIALS 10.5.3 PRODUCTS & SERVICES 10.5.4 STRATEGY 10.5.5 DEVELOPMENT 10.6 ASTRAZENECA PLC 10.6.1 OVERVIEW 10.6.2 FINANCIALS 10.6.3 PRODUCTS & SERVICES 10.6.4 STRATEGY 10.6.5 DEVELOPMENTS 10.7 AUGUREX LIFE SCIENCES CORP 10.7.1 OVERVIEW 10.7.2 FINANCIALS 10.7.3 PRODUCTS & SERVICES 10.7.4 STRATEGY 10.7.5 DEVELOPMENTS 10.8 AUSHON BIOSYSTEMS INC 10.8.1 OVERVIEW 10.8.2 FINANCIALS 10.8.3 PRODUCTS & SERVICES 10.8.4 STRATEGY 10.8.5 DEVELOPMENTS 10.9 BAYER AG 10.9.1 OVERVIEW 10.9.2 FINANCIALS 10.9.3 PRODUCTS & SERVICES 10.9.4 STRATEGY 10.9.5 DEVELOPMENTS 10.10 BECKMAN COULTER INC 10.10.1 OVERVIEW 10.10.2 FINANCIALS 10.10.3 PRODUCTS & SERVICES 10.10.4 STRATEGY 10.10.5 DEVELOPMENTS 10.11 BGI 10.11.1 OVERVIEW 10.11.2 FINANCIALS 10.11.3 PRODUCTS & SERVICES 10.11.4 STRATEGY 10.11.5 DEVELOPMENTS 10.12 BIOCRATES LIFE SCIENCES AG 10.12.1 OVERVIEW 10.12.2 FINANCIALS 10.12.3 PRODUCTS & SERVICES 10.12.4 STRATEGY 10.12.5 DEVELOPMENTS 10.13 BIOMARKER STRATEGIES 10.13.1 OVERVIEW 10.13.2 FINANCIALS 10.13.3 PRODUCTS & SERVICES 10.13.4 STRATEGY 10.13.5 DEVELOPMENTS 10.14 BIOSYSTEMS INTERNATIONAL 10.14.1 OVERVIEW 10.14.2 FINANCIALS 10.14.3 PRODUCTS & SERVICES 10.14.4 STRATEGY 10.14.5 DEVELOPMENTS 10.15 BRISTOL-MYERS SQUIBB 10.15.1 OVERVIEW 10.15.2 FINANCIALS 10.15.3 PRODUCTS & SERVICES 10.15.4 STRATEGY 10.15.5 DEVELOPMENTS 10.16 CRESCENDO BIOSCIENCE 10.16.1 OVERVIEW 10.16.2 FINANCIALS 10.16.3 PRODUCTS & SERVICES 10.16.4 STRATEGY 10.16.5 DEVELOPMENTS 10.17 EISAI CO. LTD. 10.17.1 OVERVIEW 10.17.2 FINANCIALS 10.17.3 PRODUCTS & SERVICES 10.17.4 STRATEGY 10.17.5 DEVELOPMENTS 10.18 EPIONTIS GMBH 10.18.1 OVERVIEW 10.18.2 FINANCIALS 10.18.3 PRODUCTS & SERVICES 10.18.4 DEVELOPMENTS 10.19 EPISTEM HOLDINGS PLC 10.19.1 OVERVIEW 10.19.2 FINANCIALS 10.19.3 PRODUCTS & SERVICES 10.19.4 STRATEGY 10.19.5 DEVELOPMENTS 10.20 EUROGENTEC S.A. 10.20.1 OVERVIEW 10.20.2 FINANCIALS 10.20.3 PRODUCTS & SERVICES 10.20.4 STRATEGY 10.20.5 DEVELOPMENTS 10.21 EVOTEC AG 10.21.1 OVERVIEW 10.21.2 FINANCIALS 10.21.3 PRODUCTS & SERVICES 10.21.4 STRATEGY 10.21.5 DEVELOPMENTS 10.22 GLAXOSMITHKLINE PLC 10.22.1 OVERVIEW 10.22.2 FINANCIALS 10.22.3 PRODUCTS & SERVICES 10.22.4 STRATEGY 10.22.5 DEVELOPMENTS 10.23 IPSEN 10.23.1 OVERVIEW 10.23.2 FINANCIALS 10.23.3 PRODUCTS & SERVICES 10.23.4 STRATEGY 10.23.5 DEVELOPMENTS 10.24 JOHNSON & JOHNSON 10.24.1 OVERVIEW 10.24.2 FINANCIALS 10.24.3 PRODUCTS & SERVICES 10.24.4 STRATEGY 10.24.5 DEVELOPMENTS 10.25 MERCK & CO. 10.25.1 OVERVIEW 10.25.2 FINANCIALS 10.25.3 PRODUCTS & SERVICES 10.25.4 STRATEGY 10.25.5 DEVELOPMENTS 10.26 MICROMEDIC TECHNOLOGIES LTD 10.26.1 OVERVIEW 10.26.2 PRODUCTS & SERVICES 10.26.3 STRATEGY 10.26.4 DEVELOPMENTS 10.27 MYRIAD GENETICS INC 10.27.1 OVERVIEW 10.27.2 FINANCIALS 10.27.3 PRODUCTS & SERVICES 10.27.4 STRATEGY 10.27.5 DEVELOPMENTS 10.28 NEXTGEN SCIENCES INC 10.28.1 OVERVIEW 10.28.2 FINANCIALS 10.28.3 PRODUCTS & SERVICES 10.28.4 STRATEGY 10.28.5 DEVELOPMENTS 10.29 NOVARTIS INTERNATIONAL AG 10.29.1 OVERVIEW 10.29.2 FINANCIALS 10.29.3 PRODUCTS & SERVICES 10.29.4 STRATEGY 10.29.5 DEVELOPMENTS 10.30 OCIMUM BIOSOLUTIONS LTD 10.30.1 OVERVIEW 10.30.2 FINANCIALS 10.30.3 PRODUCTS & SERVICES 10.30.4 STRATEGY 10.30.5 DEVELOPMENTS 10.31 PFIZER INC 10.31.1 OVERVIEW 10.31.2 FINANCIALS 10.31.3 PRODUCTS & SERVICES 10.31.4 STRATEGY 10.31.5 DEVELOPMENTS 10.32 PRONOTA NV 10.32.1 OVERVIEW 10.32.2 FINANCIALS 10.32.3 PRODUCTS & SERVICES 10.32.4 STRATEGY 10.32.5 DEVELOPMENTS 10.33 QUINTILES TRANSNATIONAL CORPORATION 10.33.1 OVERVIEW 10.33.2 FINANCIALS 10.33.3 PRODUCTS & SERVICES 10.33.4 STRATEGY 10.33.5 DEVELOPMENTS 10.34 QIAGEN NV 10.34.1 OVERVIEW 10.34.2 FINANCIALS 10.34.3 PRODUCTS & SERVICES 10.34.4 STRATEGY 10.34.5 DEVELOPMENTS 10.35 QUINTILES TRANSNATIONAL CORPORATION 10.35.1 OVERVIEW 10.35.2 FINANCIALS 10.35.3 PRODUCTS & SERVICES 10.35.4 STRATEGY 10.35.5 DEVELOPMENTS 10.36 ROCHE DIAGNOSTICS LIMITED 10.36.1 OVERVIEW 10.36.2 FINANCIALS 10.36.3 PRODUCTS & SERVICES 10.36.4 STRATEGY 10.36.5 DEVELOPMENT 10.37 SANOFI-AVENTIS 10.37.1 OVERVIEW 10.37.2 FINANCIALS 10.37.3 PRODUCTS & SERVICES 10.37.4 STRATEGY 10.37.5 DEVELOPMENT 10.38 SIEMENS HEALTHCARE 10.38.1 OVERVIEW 10.38.2 FINANCIALS 10.38.3 PRODUCTS & SERVICES 10.38.4 STRATEGY 10.38.5 DEVELOPMENTS 10.39 TRANS-HIT BIOMARKERS INC 10.39.1 OVERVIEW 10.39.2 FINANCIALS 10.39.3 PRODUCTS & SERVICES 10.39.4 STRATEGY 10.39.5 DEVELOPMENTS 10.40 PACIFIC BIOMARKERS INC 10.40.1 OVERVIEW 10.40.2 FINANCIALS 10.40.3 PRODUCTS & SERVICES 10.40.4 STRATEGY 10.40.5 DEVELOPMENTS 10.41 CAPRION PROTEOMICS INC. 10.41.1 OVERVIEW 10.41.2 FINANCIALS 10.41.3 PRODUCTS & SERVICES 10.41.4 STRATEGY 10.41.5 DEVELOPMENTS 10.42 PROTEOME SCIENCES PLC 10.42.1 OVERVIEW 10.42.2 FINANCIALS 10.42.3 PRODUCTS & SERVICES 10.42.4 STRATEGY 10.42.5 DEVELOPMENTS 10.43 VERMILLION INC 10.43.1 OVERVIEW 10.43.2 FINANCIALS 10.43.3 PRODUCTS & SERVICES 10.43.4 STRATEGY 10.43.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 GLOBAL BIOMARKER MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION) TABLE 2 GLOBAL BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 3 GLOBAL BIOMARKER DISCOVERY MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 4 BIOMARKER DISCOVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 5 GLOBAL BIOMARKER DISCOVERY MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 6 BIOMARKER IMAGING TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 7 GLOBAL BIOMARKER DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 8 GLOBAL BIOMARKER OMICS TECHNOLOGIES MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 9 BIOMARKER OMICS TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 10 GLOBAL PROTEOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 11 GLOBAL GENOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 12 GLOBAL TRANSCRIPTOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 13 GLOBAL METABOLOMICS BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 14 GLOBAL BIOMARKER BIOINFORMATICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 15 BIOMARKER BIOINFORMATICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 16 GLOBAL BIOMARKER MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION) TABLE 17 GLOBAL BIOMARKER APPLICATION MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 18 BIOMARKER APPLICATION MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 19 GLOBAL BIOMARKER DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 20 BIOMARKER DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 21 GLOBAL BIOMARKER APPLICATION MARKET, BY PHASES IN DRUG DISCOVERY & DEVELOPMENT PROCESS, 2009 – 2020 ($MILLION) TABLE 22 GLOBAL BIOMARKER PRECLINICAL STUDY MARKET, BY VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) TABLE 23 GLOBAL BIOMARKER PHASE I MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) TABLE 24 GLOBAL BIOMARKER PHASE II MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) TABLE 25 GLOBAL BIOMARKER PHASE III MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) TABLE 26 GLOBAL BIOMARKER PHASE IV MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) TABLE 27 PERSONALIZED MEDICINE(PM) USING BIOMARKERS IN CURRENT DRUG LABELS TABLE 28 GLOBAL BIOMARKER PERSONALIZED MEDICINE MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 29 BIOMARKER PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 31 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 32 GLOBAL BIOMARKER MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 33 GLOBAL ONCOLOGY BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION) TABLE 34 GLOBAL ONCOLOGY BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 35 GLOBAL ONCOLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 36 GLOBAL ONCOLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 37 GLOBAL ONCOLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION) TABLE 38 GLOBAL ONCOLOGY BIOMARKER MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION) TABLE 39 ONCOLOGY BIOMARKER MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 40 GLOBAL CARDIOLOGY BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION) TABLE 41 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 42 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 43 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 44 GLOBAL CARDIOLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION) TABLE 45 GLOBAL CARDIOLOGY MARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 46 COMMONLY USED CARDIAC BIOMARKER TESTS TABLE 47 BIOMARKER TESTS USED FOR PROGNOSIS TABLE 48 CARDIAC MARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 49 GLOBAL NEUROLOGY BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION) TABLE 50 GLOBAL NEUROLOGY BIOMARKER MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 51 GLOBAL NEUROLOGY BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 52 GLOBAL NEUROLOGY BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 53 GLOBAL NEUROLOGY BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION) TABLE 54 GLOBAL NEUROLOGY BIOMARKER MARKET, BY DISEASE TYPES, 2009– 2020 ($MILLION) TABLE 55 NEUROLOGY BIOMARKER MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 56 GLOBAL OTHER INDICATIONS BIOMARKER MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION) TABLE 57 GLOBAL OTHER INDICATIONS BIOMARKER MARKET REVENUE, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 58 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 59 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 60 GLOBAL OTHER INDICATION BIOMARKER MARKET, BY PHASES, 2009 – 2020 ($MILLION) TABLE 61 GLOBAL OTHER INDICATIONS BIOMARKER MARKET, BY TYPES, 2009 – 2020 ($MILLION) TABLE 62 HIV BIOMARKERS TABLE 63 RENAL BIOMARKERS TABLE 64 OTHER INDICATIONS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION) TABLE 65 BIOMARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($BILLION) TABLE 66 NORTH AMERICA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 67 NORTH AMERICA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 68 NORTH AMERICA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 69 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION) TABLE 70 NORTH AMERICA: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) TABLE 71 NORTH AMERICA: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 72 NORTH AMERICA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION) TABLE 73 NORTH AMERICA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 74 NORTH AMERICA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 75 NORTH AMERICA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION) TABLE 76 EUROPE: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 77 EUROPE: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 78 EUROPE: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 79 EUROPE: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION) TABLE 80 EUROPE: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) TABLE 81 EUROPE: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 82 EUROPE: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION) TABLE 83 EUROPE: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 84 EUROPE: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 85 EUROPE: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION) TABLE 86 ASIA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 87 ASIA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 88 ASIA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 89 ASIA: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION) TABLE 90 ASIA: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) TABLE 91 ASIA: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 92 ASIA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION) TABLE 93 ASIA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 94 ASIA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 95 ASIA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION) TABLE 96 ROW: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 97 ROW: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 98 ROW: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) TABLE 99 ROW: BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION) TABLE 100 ROW: BIOMARKERS MARKET, BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) TABLE 101 ROW: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) TABLE 102 ROW: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION) TABLE 103 ROW: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 104 ROW: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION) TABLE 105 ROW: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION) TABLE 106 MERGERS & ACQUISITIONS (JANUARY 2009 – DECEMBER 2011) TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (JANUARY 2009 – DECEMBER 2011) TABLE 108 NEW PRODUCTS LAUNCH (JANUARY 2009 – DECEMBER 2011) TABLE 109 OTHER DEVELOPMENTS (JANUARY 2009 – DECEMBER 2011) TABLE 110 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 111 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 112 ABBOTT LABORATORIES: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 113 AFFYMETRIX INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 114 AFFYMETRIX INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 115 AFFYMETRIX INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 116 AGILENT TECHNOLOGIES INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 117 AGILENT TECHNOLOGIES INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 118 AGILENT TECHNOLOGIES INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 119 AMGEN INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 120 AMGEN INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 121 ASTRAZENECA PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 122 ASTRAZENECA PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 123 ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 124 BAYER AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 125 BAYER AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 126 BAYER AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 127 BECKMAN COULTER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 128 BECKMAN COULTER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 129 BECKMAN COULTER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 130 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 131 BRISTOL-MYERS SQUIBB: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 132 BRISTOL-MYERS SQUIBB: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 133 EISAI CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) TABLE 134 EISAI CO. LTD: TOTAL REVENUES, BY SEGMENTS, 2009 – 2011 ($MILLION) TABLE 135 EISAI CO. LTD: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) TABLE 136 EPISTEM HOLDINGS PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) TABLE 137 EPISTEM HOLDINGS PLC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) TABLE 138 EPISTEM HOLDINGS PLC: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) TABLE 139 EVOTEC AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 140 EVOTEC AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 141 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2011 ($MILLION) TABLE 142 GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2011 ($MILLION) TABLE 143 GLAXOSMITHKLINE PLC: REVENUE FOR PHARMACEUTICAL SEGMENT, BY GEOGRAPHY, 2008 – 2011 ($MILLION) TABLE 144 IPSEN: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 145 IPSEN: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 146 IPSEN: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 147 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 148 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, 2008 -2010 ($MILLION) TABLE 149 MEDICAL DEVICES & DIAGNOSTICS SEGMENT REVENUE, 2008 – 2010 ($MILLION) TABLE 150 JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 151 MERCK & CO: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 152 MERCK & CO: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 153 MERCK & CO: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 154 MYRIAD GENETICS INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) TABLE 155 MYRIAD GENETICS INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) TABLE 156 NEXTGEN GROUP PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 157 NEXTGEN GROUP PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 158 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 159 NOVARTIS INTERNATIONAL AG: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 160 NOVARTIS INTERNATIONAL AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 161 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 162 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 163 PFIZER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 164 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 165 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 166 QIAGEN N.V.: GEOGRAPHIC REVENUES, 2008 – 2010 ($MILLION) TABLE 167 ROCHE: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 168 ROCHE: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 169 SANOFI-AVENTIS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 170 SANOFI-AVENTIS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 171 SANOFI-AVENTIS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 172 SIEMENS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 173 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) TABLE 174 SIEMENS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 175 PROTEOME SCIENCES PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 176 PROTEOME SCIENCES PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) TABLE 177 VERMILLION INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) TABLE 178 VERMILLION INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)

LIST OF FIGURES

FIGURE 1 OVERVIEW OF BIOMARKERS MARKET FIGURE 2 LIFE CYCLE OF A BIOMARKER FIGURE 3 BIOMARKER MARKET FIGURE 4 LEVEL OF IMPACT OF CHALLENGES FIGURE 5 BIOMARKER DISCOVERY PROCESS FIGURE 6 BIOMARKER DISCOVERY MARKET, 2011 FIGURE 7 OMICS TECHNOLOGIES & THE CENTRAL DOGMA FIGURE 8 BIOMARKER DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2011 FIGURE 9 THE CENTRAL ROLE OF MASS SPECTROMETRY IN PROTEOMICS FIGURE 10 BIOMARKER DISCOVERY USING 2-D DIGE & MS FIGURE 11 TRANSCRIPTOMICS BIOMARKER DISCOVERY FIGURE 12 BIOINFORMATICS MICROARRAY TOOLS FIGURE 13 CLUSTER ANALYSIS OF OMICS DATA FOR BIOMARKER DISCOVERY FIGURE 14 BIOMARKER SERVICES MARKET, BY SEGMENTS (%) FIGURE 15 FLOW OF CLINICAL BIOMARKER SERVICES FIGURE 16 DRUG DISCOVERY & DEVELOPMENT PROCESS FIGURE 17 BIOMARKER DISCOVERY, BY INDICATIONS, 2011 FIGURE 18 KEY GROWTH STRATEGIES (JANUARY 2009 – DECEMBER 2011)

To order this report:Genomics Industry: Biomarkers Market (Discovery Technologies, Applications & Indications) – Global Trends, Opportunities & Forecasts (2011 – 2020)

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Data Show 15 Percent Drop in Prostate Cancer Deaths

Tue, 07 Feb 2012 15:00:49 +0000

Data Show 15 Percent Drop in Prostate Cancer Deaths

PR Newswire

WASHINGTON, Feb. 7, 2012 /PRNewswire-USNewswire/ -- While more men are being diagnosed with the prostate cancer, fewer are dying from the disease. Data from the North American Association of Central Cancer Registries and the National Center for Health Statistics, Centers for Disease Control and Prevention show that in 2012, incidence rates of prostate cancer will increase slightly, while death rates from the disease will decrease. In 2011, it is estimated that 33,720 men died from the disease, while 28,170 are expected to die in 2012 – a more than 15 percent decrease. This can be attributed to both the effectiveness of early detection efforts and research that has lead to advances in treatment.

(Photo: http://photos.prnewswire.com/prnh/20110225/ZEROLOGO)

"This year alone, more than 241,000 men will be diagnosed with prostate cancer and more than 28,000 will die from the disease," said Skip Lockwood, CEO of ZERO -- The Project to End Prostate Cancer. "We are seeing the death rate decrease, but we must remain vigilant in the fight against this disease by increasing research funding, raising awareness and education, and testing men with risk factors."

In the U.S., a baby boomer turns 50 every 8.5 seconds, making the risk pool for prostate cancer larger and larger. ZERO provides free prostate cancer testing to at-risk men across the country through the Drive Against Prostate Cancer. Because of early detection efforts like the Drive, more than 90 percent of prostate cancers are discovered in the local or regional stages. When detected in these early stages, the survival rate for prostate cancer approaches 100 percent.

Over the past 25 years, the 5-year relative survival rate for all stages of prostate cancer combined has increased from 68 percent to almost 100 percent, which can be attributed to the widespread use of the PSA blood test for the disease. According to the most recent data, 10- and 15-year relative survival rates are 98 percent and 91 percent, respectively.

Research at the Department of Defense's (DOD) Prostate Cancer Research Program (PCRP) has lead to the discovery of new drugs to fight late-stage prostate cancer. Xgeva and Zytiga, both approved in the past two years, are now viable options to extend men's lives. ZERO works with the federal government to protect the valuable bench to bedside research done at the DOD, and was instrumental in keeping the PCRP funded at $80 million for fiscal year 2012.

For reasons that remain unclear, prostate cancer incidence rates are significantly higher in African Americans than in Caucasians, and death rates in African Americans remain more than twice as high as those in Caucasians. Other risk factors for prostate cancer include age and family history of the disease.

Studies suggest that a diet high in processed meat or dairy foods may also be a risk factor. Obesity may increase the risk of aggressive prostate cancer, and obesity and smoking are associated with an increased risk of dying from the disease.

ZERO believes that men should take a proactive approach to their health, and discuss prostate cancer risk factors and testing options with their doctor.

About ZERO -- The Project to End Prostate Cancer (www.zerocancer.org)
As ZERO -- The Project to End Prostate Cancer, we commit ourselves not only to reduce prostate cancer or alleviate the pain from the disease but to end it. We see a future where all men who have been diagnosed with prostate cancer will be cured or manage their illness with good quality of life, with the support they need to minimize physical and emotional suffering and to cope effectively throughout their cancer journeys.

To accomplish our goal, we increase research funds from the federal government to find new treatments and we fund local grants to end prostate cancer through our national event series, the Great Prostate Cancer Challenge. We conduct free testing through the Drive Against Prostate Cancer mobile testing program and educate patients, families and those at risk.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Skip Lockwood
http://www.profnetconnect.com/skip_lockwood

SOURCE ZERO - The Project to End Prostate Cancer

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

Tue, 07 Feb 2012 13:00:00 +0000

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

PR Newswire

BOTHELL, WA and VANCOUVER, BC, Feb. 7, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, Chief Executive Officer, will provide a corporate presentation at the following investor conferences:

BIO CEO & Investor Conference on Tuesday, February 14 at 8:30 a.m. ET at the Waldorf Astoria Hotel in New York City
Leerink Swann Global Healthcare Conference on Wednesday, February 15 at 11:30 a.m. ET at the Waldorf Astoria Hotel in New York City
Citi Global Health Care Conference on Tuesday, February 28 at 4 p.m. ET at the Waldorf Astoria Hotel in New York City
RBC Capital Markets Global Healthcare Conference on Wednesday, February 29 at 8:00 a.m. ET at the New York Palace Hotel in New York City
Cowen Annual Health Care Conference on Monday, March 5 at 1:30 p.m. ET at the Boston Marriott Copley Place in Boston

Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 90 days.

About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that subsequent studies may not confirm earlier trial results, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Quarterly Report on Form 10-Q for third quarter ended September 30, 2011. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.

Spectros Corporation Sales Revenue Up 69% in 2011

Tue, 07 Feb 2012 12:00:00 +0000

Spectros Corporation Sales Revenue Up 69% in 2011

PR Newswire

PORTOLA VALLEY, Calif., Feb. 7, 2012 /PRNewswire/ --Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.

"This accelerating growth continues to send a strong signal that the market is embracing the Spectros broadband tissue oximetry," notes CFO John Bagnatori.

Spectros T-Stat® is the only broadband tissue oximeter on the market in the U.S., Europe, and Asia. T-Stat's proprietary broadband oximetry relies on over 260 wavelengths of light, compared just 2-4 wavelengths used in other oximeters. T-Stat competes with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix.

An expanded array of products, including broadband infrared Ceres™ cerebral probes and multi-site T-Stat monitors are under development.

About Spectros

Spectros markets advanced molecular devices that shed light on ischemia and cancer. Spectros is also developing molecular imaging contrast agents for surgical guidance during breast and prostate cancer surgeries, currently undergoing phase I/II clinical trials. Spectros is a venture-supported concern.

(Note: Forward-looking statements do not constitute an offer for investment nor a guarantee of future events or returns. Certain applications described above have not been reviewed by the FDA, and are therefore labeled for investigational use only. T-Stat is a trademark of Spectros. INVOS is a trademark of Somanetics and Covidien). FORE-SIGHT is a trademark of CAS Medical.

For further information, visit www.spectros.com.

Web Site: http://www.spectros.com

SOURCE Spectros

FDA News & Notes - Week of February 6, 2012

Mon, 06 Feb 2012 23:49:04 +0000

FDA News & Notes - Week of February 6, 2012

PR Newswire

SILVER SPRING, Md., Feb. 6, 2012 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of February 6, 2012.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.

Meetings, Workshops and Congressional Testimony:

Wednesday, 2/8 – The Oncologic Drugs Advisory Committee Meeting discusses a supplemental biologics application for Xgeva (denosumab) to treat men with castrate-resistant prostate cancer who are at high risk of developing bone metastases or have had their cancer spread to the bones. 8 a.m., 10903 New Hampshire Avenue, Building 31, Room 1503, Silver Spring, Md.
Press Office Contact: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov

Thursday, 2/9 – The Oncologic Drugs Advisory Committee Meeting discusses a supplemental new drug application for Dacogen (decitabine) to treat patients with acute myelogenous leukemia in people ages 65 years or older who are not considered candidates for induction chemotherapy. 8 a.m., 10903 New Hampshire Avenue, Building 31, Room 1503, Silver Spring, Md.
Press Office Contact: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Thursday, 2/9 – The House Committee on Energy and Commerce, Subcommittee on Health holds a hearing on generic drug and biosimilar user fees and drug shortages. Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research is scheduled to testify. 10 a.m., 2123 Rayburn House Office Building, Washington, D.C.
Press Office Contact: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Thursday, 2/9 – The Anesthetic and Analgesic Drug Products Advisory Committee discusses the efficacy and safety data for supplemental new drug application for QUTENZA (capsaicin 8%) Patch by NeurogesX Inc. for proposed indication of management of HIV-related nerve pain. 8:30 a.m., DoubleTree by Hilton Hotel Washington DC/Silver Spring, 8727 Colesville Road, Silver Spring, Md.
Press Office Contact: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov

Friday, 2/10 – The Neurological Devices Panel of the Medical Devices Advisory Committee makes recommendations regarding the possible reclassification of cranial electrotherapy stimulator devices. Hilton Washington DC North/Gaithersburg, 620 Perry Parkway, Gaithersburg, Md.
Press Office Contact: Michelle Bolek, 301-796-2973, michelle.bolek@fda.hhs.gov

Friday, 2/10 – The Cellular, Tissue and Gene Therapies Advisory Committee meets by teleconference, in open session, to consider updates of the research programs in the Cellular and Tissue Therapy Branch, Office of Cellular, Tissue and Gene Therapies, at the FDA's Center for Biologics Evaluation and Research. Those attending must be onsite. 2 p.m., National Institutes of Health, 9000 Wisconsin Avenue, Building 29B, Conference Room A-B, Bethesda, Md.
Press Office Contact: Rita Chappelle, 301-796-4672, rita.chappelle@fda.hhs.gov

FDA Office of Public Affairs Contact Information:

Call or email FDA Office of Public Affairs, 301-796-4540, fdaopa@fda.hhs.gov
List of FDA Press Officers and beats

More Resources:

FDA News and Events

FDA Photos (Flickr)

Consumer Health Information

SOURCE U.S. Food and Drug Administration

Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook

Mon, 06 Feb 2012 21:01:00 +0000

Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook

- Full-Year Product Revenue Increased 17 Percent Compared with 2010 -

- Delivered Net Income of $7.8 Million -

- Launched Oncotype DX® DCIS Score and MMR Testing -

- Conference Call Today at 4:30 p.m. ET -

PR Newswire

REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the year ended December 31, 2011.

Total revenue for the year ended December 31, 2011 increased to $206.1 million, compared with $178.1 million in 2010, an increase of 16 percent. Product revenue was $204.8 million, compared with $174.9 million in 2010, an increase of 17 percent. Contract revenue comprised the balance of total revenue for each of these periods.

Net income was $7.8 million for the year ended December 31, 2011, compared with $4.3 million in 2010. Basic and diluted net income per share applicable to common stockholders was $0.27 and $0.26, respectively in 2011, compared with $0.15 and $0.14 per share, respectively, in 2010.

Total revenue for the fourth quarter of 2011 increased to $53.4 million, compared with $47.1 million in the fourth quarter of 2010. Product revenue was $53.2 million in the fourth quarter of 2011, compared with $46.3 million for the fourth quarter of 2010, an increase of 15 percent. Net income in the fourth quarter of 2011 was $2.6 million, compared with $1.7 million in the fourth quarter of 2010. Basic and diluted net income per share applicable to common stockholders was $0.09 and $0.08, respectively, for the fourth quarter of 2011, compared with $0.06 per share in the fourth quarter of 2010.

"In 2011, we increased our financial strength and generated $7.8 million in profit while making important progress across our commercial and pipeline programs," said Kim Popovits, President and Chief Executive Officer of Genomic Health. "As we look ahead, we remain focused on providing solutions that deliver better outcomes for cancer patients worldwide by continuing to expand our Oncotype DX^® services to include prostate cancer and by accelerating the development of next generation genomic and genetic services."

In a separate press release issued today the company announced plans to establish a wholly owned genetics subsidiary with the intention of making clinically relevant genetic information available to physicians and patients beginning in 2013. Genomic Health plans to invest up to $20 million in the new subsidiary over the next two years and has incorporated this into its 2012 financial outlook provided below.

Additional Year-End and Fourth Quarter 2011 Financial Results

Total operating expenses for the year ended December 31, 2011 were $197.9 million, including cost of product revenues of $33.8 million, compared with total operating expenses for the comparable period in 2010 of $174.2 million, including cost of product revenues of $34.6 million. Included in operating expenses for the year ended December 31, 2011 were non-cash charges of $19.0 million, including $11.7 million of stock-based compensation expense and $7.3 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2010 of $17.5 million, including $10.3 million of stock-based compensation expense and $7.2 million of depreciation and amortization expenses.

Cash and cash equivalents and short-term investments at December 31, 2011 were $100.5 million, compared with $76.8 million at December 31, 2010, an increase of $23.7 million.

Total operating expenses for the fourth quarter of 2011 were $50.7 million, including cost of product revenues of $7.4 million, compared with total operating expenses for the comparable period in 2010 of $45.8 million, including cost of product revenues of $8.7 million. Included in operating expenses for the fourth quarter of 2011 were non-cash charges of $4.7 million, including $2.9 million of stock-based compensation expense and $1.8 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2010 of $4.2 million, including $2.3 million of stock-based compensation expense and $1.9 million of depreciation and amortization expenses.

More than 66,600 Oncotype DX test results were delivered for the year ended December 31, 2011, an increase of 16 percent, compared with more than 57,270 test results delivered in 2010. In the fourth quarter of 2011, more than 17,080 Oncotype DX test results were delivered, an increase of 13 percent, compared with more than 15,180 test results delivered in the same period in 2010.

2012 Financial Outlook

The company is providing the following financial guidance for the full year ending December 31, 2012:

Total revenue of $230 to $240 million
Oncotype DX test results delivered of 75,000 to 77,000
Full-year net income of $5 to $8 million before an incremental loss of up to $8 million in new subsidiary

"In 2012, we plan to further strengthen our cancer genomics business by making key investments aimed at driving top-line revenue growth with positive cash from operations," said Dean Schorno, Chief Financial Officer of Genomic Health. "Over the next several years, we plan to aggressively invest in what we believe are significant opportunities presented by our growing worldwide business, the recent launch of our breast cancer DCIS Score, our prostate cancer program and next generation products."

Recent Business Highlights:

Oncotype DX Breast Cancer Commercial Progress

Began providing the Oncotype DX DCIS Score to physicians and patients worldwide.
Established node-positive reimbursement for an additional eight million U.S. lives through policies or arrangements with BCBS Michigan, Tufts Associated Health Maintenance Organization, Presbyterian Health Plan, BCBS South Carolina HMO and Priority Health.
Established Medicaid reimbursement for node-negative breast cancer in Minnesota, Michigan, Vermont and Oregon.
The British Columbia Breast Tumour Group recommended the Ministry of Health begin paying for Oncotype DX for node-negative breast cancer patients in British Columbia, Canada.
Secured reimbursement coverage with a leading German Sick fund for patients participating in a study conducted by the West German Study Group.
NCIC researchers in Canada began enrolling node-positive patients in the NCI-sponsored RxPONDER trial, which requires the Oncotype DX Recurrence Score® for study entry.
Established distribution agreements to provide Oncotype DX in Hungary, Romania and Peru.

Oncotype DX Colon Cancer Commercial Progress

The Journal of Clinical Oncology published results from the landmark QUASAR clinical validation study, which demonstrated that the Oncotype DX colon cancer test predicts recurrence risk in stage II colon cancer patients following surgery.
Began providing mismatch repair (MMR) testing for recurrence risk that allows physicians to identify the approximately 15 percent of stage II colon cancer patients with MMR-deficient tumors, who have low recurrence risk and thus may be more appropriately considered for observation following surgery.
Presented results of the first clinical decision making study of the Oncotype DX colon cancer test at the Gastrointestinal (GI) Cancers Symposium, demonstrating a 29 percent change in treatment recommendations.
Established reimbursement for an additional 3.8 million U.S. lives through policies or arrangements with Wellmark BCBS of Iowa, Wellmark BCBS of South Dakota, Wisconsin Physicians Service Insurance Corporation, Preferred One and AvMed.

Product Pipeline, Peer-Reviewed Publications and Medical Meeting Presentations

Initiated large clinical validation study of prostate cancer test.
Accelerated next generation sequencing (NGS) program in development to be used in clinical studies later this year.
Presented 16 Oncotype DX studies at the San Antonio Breast Cancer Symposium (SABCS) in December, including:
- Complete results from the study of Oncotype DX in patients with DCIS.
- Multiple international studies on changing treatment decisions and/or cost effectiveness of Oncotype DX in the United Kingdom, Germany, France, Ireland, Israel, Canada, Hungary, Japan, Singapore, Australia, and Venezuela.
- Positive results from the first clinical outcomes study for biomarker discovery using NGS for whole transcriptome profiling of fixed tumor specimens.
Presented results from a large clinical study in prostate cancer at the Genitourinary (GU) Cancer Symposium evaluating the relationship of microRNAs, a novel class of biomarkers, to clinical outcomes for patients with early stage prostate cancer.

Conference Call Details

To access the live conference call on February 6 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately two hours after the call through February 13, and may be accessed by dialing (855) 859-2056 from the United States and Canada or +1(404) 537-3406 internationally. The replay passcode is 45978166.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to the predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of December 31, 2011, more than 10,000 physicians in over 65 countries had ordered more than 265,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's 2011 fourth quarter and annual results; 2012 financial guidance, including the company's expectations regarding the number of test results delivered, total revenue and net income before investments; our plans to focus on continuing to expand our Oncotype DX services and to accelerate our next generation product development, and the focus of new product development; our expectations regarding the business of a subsidiary to be formed; our belief regarding our ability to leverage our global infrastructure in cancer to integrate the human genome more broadly into medical practice; our plans to make investments aimed at driving top-line revenue growth with positive cash from operations; our plans to invest in our business and the amounts and areas of investments; the focus and attributes of the company's product pipeline; the ability of the company to develop additional tests in the future; and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop, both domestically and abroad; our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; the results of our year end audit; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the period ended September 30, 2011. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Genomic Health, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)

	For the Three Months Ended		For the Twelve Months Ended
	December 31,		December 31,
	2011	2010	2011	2010
	(Unaudited)		(Unaudited)

REVENUES:
Product revenues	$ 53,155	$ 46,317	$ 204,766	$ 174,870
Contract revenues	242	799	1,345	3,231
Total revenues	53,397	47,116	206,111	178,101

OPERATING EXPENSES:
Cost of product revenues	7,352	8,707	33,832	34,634
Research and development	10,282	9,272	39,864	33,225
Selling and marketing	22,393	18,536	83,613	71,405
General and administrative	10,638	9,278	40,543	34,913
Total operating expenses	50,665	45,793	197,852	174,177

Income from operations	2,732	1,323	8,259	3,924

Interest income	4	58	221	232
Other income (expense), net	(14)	(18)	(205)	(4)

Income before income taxes	2,722	1,363	8,275	4,152

Income tax expense (benefit)	163	(322)	429	(136)

Net income	$ 2,559	$ 1,685	$ 7,846	$ 4,288

Basic net income per share	$ 0.09	$ 0.06	$ 0.27	$ 0.15
Diluted net income per share	$ 0.08	$ 0.06	$ 0.26	$ 0.14

Shares used to compute basic net income per share	29,644	28,910	29,395	28,815
Shares used to compute diluted net income per share	31,062	29,763	30,754	29,653

Genomic Health, Inc.
Condensed Consolidated Balance Sheets
(in thousands)

	As of	As of
	December 31, 2011	December 31, 2010
	(Unaudited)	(Unaudited)
Cash and cash equivalents	$ 32,869	$ 31,183
Short-term investments	67,605	45,635
Accounts receivable, net	21,077	14,306
Prepaid expenses and other current assets	7,444	6,541
Total current assets	128,995	97,665

Property and equipment, net	9,443	10,345
Restricted cash	107	608
Other assets	4,453	2,243
Total assets	$ 142,998	$ 110,861

Accounts payable	$ 7,025	$ 3,968
Accrued expenses and other current liabilities	17,265	16,305
Deferred revenues	2,060	2,821
Other liabilities	1,289	1,657
Stockholders’ equity	115,359	86,110
Total liabilities and stockholders’ equity	$ 142,998	$ 110,861


The condensed consolidated balance sheet at December 31, 2010 has been derived from the
audited consolidated financial statements at that date included in the Company's Form 10-K
for the fiscal year ended December 31, 2010.

SOURCE Genomic Health, Inc.

FDA News & Notes -- Week of February 6, 2012

Mon, 06 Feb 2012 18:41:05 +0000

FDA News & Notes -- Week of February 6, 2012

PR Newswire

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.

Meetings, Workshops and Congressional Testimony:

Wednesday, 2/8 – The Oncologic Drugs Advisory Committee opens a two-day meeting with a discussion on a supplemental biologics application for Xgeva (denosumab) to treat men with castrate-resistant prostate cancer who are at high risk of developing bone metastases or have had their cancer spread to their bones. On Thursday morning the committee discusses a supplemental new drug application for Dacogen (decitabine) to treat patients with acute myelogenous leukemia in people ages 65 years and older who are not considered candidates for induction chemotherapy. The afternoon session focuses on a new drug application for Pixuvri (pixantrone dimaleate) for use as a single agent treatment in patients with relapsed or difficult to treat aggressive non-Hodgkin's lymphoma who received two or more prior lines of therapy. 8 a.m., 10903 New Hampshire Avenue, Building 31, Room 1503, Silver Spring, Md.
Press Office Contact: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Thursday, 2/9 – The House Committee on Energy and Commerce, Subcommittee on Health holds a committee hearing on generic drug and biosimilar user fees. Drug shortages will also be discussed. Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research is scheduled to testify. 10 a.m., 2123 Rayburn House Office Building, Washington, D.C.
Press Office Contact: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Thursday, 2/9 – The Anesthetic and Analgesic Drug Products Advisory Committee discusses the available efficacy and safety data for a supplemental new drug application for Qutenza (capsaicin 8%) Patch, by NeurogesX Inc., for the use of management of nerve pain related to HIV-associated peripheral neuropathy (such as nerve pain in the feet and legs). 8:30 a.m., Double Tree by Hilton Hotel, Washington DC/Silver Spring, 8727 Colesville Road., Silver Spring, Md.
Press Office Contact: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov

Friday, 2/10 – The Neurological Devices Panel of the Medical Devices Advisory Committee makes recommendations regarding the possible reclassification of cranial electrotherapy stimulator (CES) devices. The discussion includes the existing data to support CES safety and effectiveness and whether the data are sufficient to develop special controls to support regulation of these devices under Class II. 8 a.m., Hilton Washington DC North/Gaithersburg, Salons A, B, C and D, 620 Perry Parkway, Gaithersburg, Md.
Press Office Contact: Michelle Bolek, 301-796-2973, michelle.bolek@fda.hhs.gov

Friday, 2/10 – The Cellular, Tissue and Gene Therapies Committee meets to hear updates and discuss, by teleconference, a report of the site visit to observe intramural research conducted by the Gene and Tissue Therapy Branch of the FDA's Center for Biologics Evaluation and Research. Attendees must be present. 2 p.m., Building 29B, Conference Room A-B, National Institutes of Health, 9000 Wisconsin Avenue, Bethesda, Md.
Press Office Contact: Rita Chappelle, 301-796-4672, rita.chappelle@fda.hhs.gov

FDA Office of Public Affairs Contact Information:

Call or email FDA Office of Public Affairs, 301-796-4540, fdaopa@fda.hhs.gov

List of FDA Press Officers and beats

More Resources:
FDA News and Events

FDA Photos (Flickr)

Consumer Health Information

SOURCE U.S. Food and Drug Administration

CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015

Mon, 06 Feb 2012 09:38:00 +0000

CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015

PR Newswire

ALBANY, New York, February 6, 2012 /PRNewswire/ --

In the news release, "Global Osteoporosis Market is Expected to Attain a Market Size of USD 6.8 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015" issued on 31 Jan 2012 11:30 GMT, by Transparency Market Research over PR Newswire, we are advised by a representative of the company that in the headline "Market Size of USD 6.8 billion" has been changed to "Market Size of USD 11.4 billion".

According to a new report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast (2010-2015)" Global Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD 11.4 billion in 2015 at a CAGR of 9.2% over the period 2010 to 2015. Bisphosphonate segment accounted for the largest share at 62.0% of weight management market in 2010. China Osteoporosis market will be worth USD 2.5 billion in 2015.

Browse full report at: http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

In 2009, the Global Osteoporosis Drug Market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted healthy market share and showed an average sales growth rate of about of 20% in the past 2 years.

Amgen's Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8 billion in 2015.

Our research indicates that the Osteoporosis drug pipeline is going strong with various phases of clinical development. Phase III has first-in-class products such as odanacatib, which possess a novel mechanism of action to combat Osteoporosis. Aprela is another drug in the stage of development.

The Chinese Osteoporosis drug market is expected to grow at a CAGR of 13.5% from 2010 to 2015. Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug market. The other key growth drivers for Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education.

To gain a competitive advantage, market players should develop cost-competitive drugs with easy dosage pattern, which promote bone building effectively. Large numbers of patients are unable to comply with the strict dosage schedule of traditional Osteoporosis drugs. Further research and development can address the unmet need by coming up with drugs that have a convenient dosage schedule with better efficacy and safety compared to traditional treatment of Osteoporosis.

This report provides in-depth analysis of global and China Osteoporosis Market based on following segmentation:

Geographic Markets
- Global
- China

By Segment
- Bisphosphonate Drugs
- SERM Drugs
- Parathyroid Hormone Drugs
- Calcitonin Drugs
- Denosumab Drugs

Related & Recently Published Reports by Transparency Market Research

Energy Efficient Lamps Market

Diabetes Devices Market

Cardiovascular Devices Market

Minimally Invasive Surgery Market

Browse all Pharmaceutical Market Research Reports

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Ms Amita
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
http://www.transparencymarketresearch.com/
http://www.twease.org/
http://blog.transparencymarketresearch.com/
http://transparencymarketresearch.blogspot.com/

CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015

Mon, 06 Feb 2012 09:38:00 +0000

CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015

PR Newswire

ALBANY, New York, February 6, 2012 /PRNewswire/ --

Browse full report at: http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

This report provides in-depth analysis of global and China Osteoporosis Market based on following segmentation:

Geographic Markets
- Global
- China

By Segment
- Bisphosphonate Drugs
- SERM Drugs
- Parathyroid Hormone Drugs
- Calcitonin Drugs
- Denosumab Drugs

Related & Recently Published Reports by Transparency Market Research

Energy Efficient Lamps Market

Diabetes Devices Market

Cardiovascular Devices Market